Fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting

References

• Grunberg SM, Rolski J, Strausz J et al. Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial. Lancet Oncol.10, 549–558 (2009).
   PubMed Web of Science ®Google Scholar
• Herrstedt J, Apornwirat W, Shaharyar A et al. Phase III trial of casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy. J. Clin. Oncol.27, 5363–5369 (2009).
   PubMed Web of Science ®Google Scholar
• Hesketh PJ, Grunberg SM, Gralla RJ et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin – the Aprepitant Protocol 052 Study Group. J. Clin. Oncol.21, 4112–4119 (2003).
   PubMed Web of Science ®Google Scholar
• Poli-Bigelli S, Rodrigues-Pereira J, Carides AD et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer97, 3090–3098 (2003).
   PubMed Web of Science ®Google Scholar
• Warr DG, Hesketh PJ, Gralla RJ et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J. Clin. Oncol.23, 2822–2830 (2005).
   PubMed Web of Science ®Google Scholar
• Coates A, Abraham S, Kaye SB et al. On the receiving end – patient perception of the side-effects of cancer chemotherapy. Eur. J. Cancer Clin. Oncol.19, 203–208 (1983).
   PubMedGoogle Scholar
• de Boer-Dennert M, de Wit R, Schmitz PI et al. Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists. Br. J. Cancer76, 1055–1061 (1997).
   PubMed Web of Science ®Google Scholar
• Griffin AM, Butow PN, Coates AS et al. On the receiving end. V: Patient perceptions of the side effects of cancer chemotherapy in 1993. Ann. Oncol.7, 189–195 (1996).
   PubMed Web of Science ®Google Scholar
• Roila F, Herrstedt J, Aapro M et al. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann. Oncol.21(Suppl. 5), v232–v243 (2010).
   Google Scholar
• Maggi CA. The mammalian tachykinin receptors. Gen. Pharmacol.26, 911–944 (1995).
   PubMedGoogle Scholar
• Andrews PL, Bhandari P. Resinferatoxin, an ultrapotent capsaicin analogue, has anti-emetic properties in the ferret. Neuropharmacology32, 799–806 (1993).
   PubMed Web of Science ®Google Scholar
• Carpenter DO, Briggs DB, Strominger N. Peptide-induced emesis in dogs. Behav. Brain Res.11, 277–281 (1984).
   PubMed Web of Science ®Google Scholar
• Snider RM, Constantine JW, Lowe JA III et al. A potent nonpeptide antagonist of the substance P (NK1) receptor. Science251, 435–437 (1991).
   PubMed Web of Science ®Google Scholar
• Hale JJ, Mills SG, MacCoss M et al. Phosphorylated morpholine acetal human neurokinin-1 receptor antagonists as water-soluble prodrugs. J. Med. Chem.43, 1234–1241 (2000).
   PubMed Web of Science ®Google Scholar
• Huskey SE, Dean BJ, Doss GA et al. The metabolic disposition of aprepitant, a substance P receptor antagonist, in rats and dogs. Drug Metab. Dispos.32, 246–258 (2004).
   PubMed Web of Science ®Google Scholar
• Huskey SE, Dean BJ, Bakhtiar R et al. Brain penetration of aprepitant, a substance P receptor antagonist, in ferrets. Drug Metab. Dispos.31, 785–791 (2003).
   PubMed Web of Science ®Google Scholar
• Bergstrom M, Hargreaves RJ, Burns HD et al. Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant. Biol. Psychiatry55, 1007–1012 (2004).
   PubMed Web of Science ®Google Scholar
• Huskey SE, Luffer-Atlas D, Dean BJ et al. Substance P receptor antagonist I: conversion of phosphoramidate prodrug after i.v. administration to rats and dogs. Drug Metab. Dispos.27, 1367–1373 (1999).
   PubMed Web of Science ®Google Scholar
• Lasseter KC, Gambale J, Jin B et al. Tolerability of fosaprepitant and bioequivalency to aprepitant in healthy subjects. J. Clin. Pharmacol.47, 834–840 (2007).
   PubMed Web of Science ®Google Scholar
• Sanchez RI, Wang RW, Newton DJ et al. Cytochrome P450 3A4 is the major enzyme involved in the metabolism of the substance P receptor antagonist aprepitant. Drug Metab. Dispos.32, 1287–1292 (2004).
   PubMed Web of Science ®Google Scholar
• Majumdar AK, Howard L, Goldberg MR et al. Pharmacokinetics of aprepitant after single and multiple oral doses in healthy volunteers. J. Clin. Pharmacol.46, 291–300 (2006).
   PubMed Web of Science ®Google Scholar
• Tattersall FD, Rycroft W, Cumberbatch M et al. The novel NK1 receptor antagonist MK-0869 (L-754,030) and its water soluble phosphoryl prodrug, L-758,298, inhibit acute and delayed cisplatin-induced emesis in ferrets. Neuropharmacology39, 652–663 (2000).
   PubMed Web of Science ®Google Scholar
• Navari RM, Reinhardt RR, Gralla RJ et al. Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group. N. Engl. J. Med.340, 190–195 (1999).
   PubMed Web of Science ®Google Scholar
• Campos D, Pereira JR, Reinhardt RR et al. Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone. J. Clin. Oncol.19, 1759–1767 (2001).
   PubMed Web of Science ®Google Scholar
• Cocquyt V, Van BS, Reinhardt RR et al. Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis. Eur. J. Cancer37, 835–842 (2001).
   PubMed Web of Science ®Google Scholar
• Van Belle S, Lichinitser MR, Navari RM et al. Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869. Cancer94, 3032–3041 (2002).
   PubMed Web of Science ®Google Scholar
• Chawla SP, Grunberg SM, Gralla RJ et al. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting. Cancer97, 2290–2300 (2003).
   PubMed Web of Science ®Google Scholar
• Rapoport BL, Jordan K, Boice JA et al. Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study. Support Care Cancer18, 423–431 (2010).
   PubMed Web of Science ®Google Scholar
• Schmoll HJ, Aapro MS, Poli-Bigelli S et al. Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment. Ann. Oncol.17, 1000–1006 (2006).
   PubMed Web of Science ®Google Scholar
• Grunberg S, Chua D, Maru A et al. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol – EASE. J. Clin. Oncol.29, 1495–1501 (2011).
   PubMed Web of Science ®Google Scholar
• de Wit R, Herrstedt J, Rapoport B et al. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled Phase III clinical trials. Eur. J. Cancer40, 403–410 (2004).
   PubMed Web of Science ®Google Scholar
• Herrstedt J, Muss HB, Warr DG et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy. Cancer104, 1548–1555 (2005).
   PubMed Web of Science ®Google Scholar
• Ruhlmann CH, Herrstedt J. Safety evaluation of aprepitant for the prevention of chemotherapy-induced nausea and vomiting. Expert Opin. Drug Saf.10, 449–462 (2011).
   PubMed Web of Science ®Google Scholar
• McCrea JB, Majumdar AK, Goldberg MR et al. Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone. Clin. Pharmacol. Ther.74, 17–24 (2003).
   PubMed Web of Science ®Google Scholar
• Marbury TC, Ngo PL, Shadle CR et al. Pharmacokinetics of oral dexamethasone and midazolam when administered with single-dose intravenous 150 mg fosaprepitant in healthy adult subjects. J. Clin. Pharmacol.51(12), 1712–1720 (2011).
   PubMed Web of Science ®Google Scholar
• Depre M, Van HA, Oeyen M et al. Effect of aprepitant on the pharmacokinetics and pharmacodynamics of warfarin. Eur. J. Clin. Pharmacol.61, 341–346 (2005).
   PubMed Web of Science ®Google Scholar
• Arpornwirat W, Albert I, Hansen VL et al. Phase II trial results with the novel neurokinin-1 receptor antagonist casopitant in combination with ondansetron and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in cancer patients receiving moderately emetogenic chemotherapy. Cancer115, 5807–5816 (2009).
   PubMed Web of Science ®Google Scholar
• Roila F, Rolski J, Ramlau R et al. Randomized, double-blind, dose-ranging trial of the oral neurokinin-1 receptor antagonist casopitant mesylate for the prevention of cisplatin-induced nausea and vomiting. Ann. Oncol.20, 1867–1873 (2009).
   PubMed Web of Science ®Google Scholar
• Rudd J, Ngan MP, Cantoreggi S, Pietra C. The co-administration of the NK1 receptor antagonist netupitant with palonosetron and dexamethasone reduces cisplatin-induced acute and delayed emesis in ferrets. Support Care Cancer19(Suppl. 2), S155 (2011).
   PubMed Web of Science ®Google Scholar
• Hesketh PJ, Sanz-Altamira P, Bushey J, and Hesketh AM. Prospective evaluation of the incidence of delayed nausea and vomiting in patients with colorectal cancer receiving oxaliplatin-based chemotherapy. Support Care Cancer doi:10.1007/s00520-011-1180-2 (2011) (Epub ahead of print).
   Google Scholar
• Hesketh PJ, Bosnjak SM, Nikolic V, Rapoport B. Incidence of delayed nausea and vomiting in patients with colorectal cancer receiving irinotecan-based chemotherapy. Support Care Cancer19, 2063–2066 (2011).
   PubMed Web of Science ®Google Scholar
• Hesketh PJ, Wright O, Rosati G et al. Single-dose intravenous casopitant in combination with ondansetron and dexamethasone for the prevention of oxaliplatin-induced nausea and vomiting: a multicenter, randomized, double-blind, active-controlled, two arm, parallel group study. Support Care Cancer doi:10.1007/s00520-011-1235-4 (2011) (Epub ahead of print).
   Google Scholar
• Martin M, Diaz-Rubio E, Sánshez A, Almenarez J, Lopez-Vega M. The natural course of emesis after carboplatin treatment. Acta. Oncol.29, 593–595 (1990).
   PubMed Web of Science ®Google Scholar